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Background: Pain in the head neck area is an early symptom in oral cancer, supporting the hypothesis that cancer
cells control the activities of surrounding nociceptors at the site of the tumor. Several reports implicate TRPV1 and
TRPA1 in cancer pain, although there is a large gap in knowledge since the mechanisms for tumor-induced activation
of these TRP receptors are unknown. Interestingly, TRP-active lipids such as linoleic acid, arachidonic acid,
hydroxyoctadecadienoic acid and hydroxyeicosatetraenoic acid are significantly elevated in the saliva of oral
cancer patients compared to normal patients, supporting a possible linkage between these lipids and oral
cancer pain. We therefore hypothesize that oral squamous cell carcinomas release certain lipids that activate
TRPV1 and/or TRPA1 on sensory neurons, contributing to the development of oral cancer pain.
Methods: Lipid extracts were made from conditioned media of three human oral squamous cell carcinoma (OSCC) cell
lines as well as one normal human oral keratinocytes cell line. These were then injected intraplantarly into rat hindpaws to
measure spontaneous nocifensive behavior, as well as thermal and mechanical allodynia. For interventional experiments,
the animals were pretreated with AMG517 (TRPV1 antagonist) or HC030031 (TRPA1 antagonist) prior to extract injection.
Results: These studies demonstrate that lipids released from the three OSCC cell lines, but not the normal cell line, were
capable of producing significant spontaneous nocifensive behaviors, as well as thermal and mechanical allodynia. Notably
each of the cell lines produced a different magnitude of response for each of three behavioral assays. Importantly,
pre-treatment with a TRPVI antagonist blocked lipid-mediated nocifensive and thermal hypersensitivity, but not
mechanical hypersensitivity. In addition, pre-treatment with a TRPA1 antagonist only reversed thermal hypersensitivity
without affecting lipid-induced nocifensive behavior or mechanical allodynia.
Conclusions: These data reveal a novel mechanism for cancer pain and provide strong direction for future studies
evaluating the cellular mechanism regulating the TRP-active lipids by OSCC tumors.
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Pain due to cancer is notoriously difficult to treat, adds
substantially to the emotional burden of having cancer,
and is more frequently observed with certain cancer types
such as with head and neck carcinomas (HNC). Indeed,
70–85 % of HNC patients report pain as their major
symptom [1–4]. Patients typically report spontaneous pain
as well as movement-related pain (i.e., mechanical* Correspondence: ruparels@uthscsa.edu
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creativecommons.org/publicdomain/zero/1.0/allodynia) at the primary site of tumor development such
as the tongue, floor of the mouth, larynx, oropharynx,
hypopharynx and salivary glands [5, 6]. Many patients sub-
sequently require opiates and tolerance rapidly develops
for many HNC pain patients [7].
Despite the occurrence of pain in cancer, there is incom-
plete understanding of the mechanisms by which oral tu-
mors evoke pain. Because pain is often the first symptom of
oral cancer, occurring even when the tumor is still quite
small in size, it is likely that oral cancer cells control the ac-
tivities of surrounding nociceptors at the site of the tumor.
A major class of trigeminal nociceptors express transientrticle distributed under the terms of the Creative Commons Attribution License
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TRP vanilloid 1 (TRPV1), which has been implicated in oral
cancer pain [7, 11]. However, the mechanism by which
TRPV1 is activated during oral cancer is unknown.
Many polyunsaturated fatty acids (PUFA) are known
to activate or sensitize TRPV1 [12–19]. However, no
prior studies have evaluated the role of these lipids in
mediating cancer pain. Interestingly, clinical studies have
demonstrated that several TRP-active PUFAs such as
linoleic acid, arachidonic acid, hydroxyoctadecadienoic
acid (HODE) and hydroxyeicosatetraenoic acid (HETE)
are significantly elevated in the saliva of oral cancer
patients compared to normal patients, supporting a pos-
sible linkage between these lipids and oral cancer pain
[20]. In addition, TRPA1 is co-expressed with TRPV1
[21], is also activated by oxidized lipids [12, 22–24],
modulates the activity of TRPV1 [25, 26] and may
participate in cancer pain [27]. Accordingly, we tested
the novel hypothesis that oral squamous cell carcinomas
release certain oxidized lipids that activate TRPV1 and
TRPA1 on sensory neurons, contributing to the develop-
ment of oral cancer pain.
Methods
Cells lines
Human oral squamous cell carcinoma (OSCC) cell lines;
HSC2, HSC3 and HSC4 were purchased from Health Sci-
ence Research Resources Bank, Japan. These cell lines were
established from tumors obtained from male patients with
the primary site of tumor being either the floor of the
mouth or the tongue [28]. The OSCC cell lines were culti-
vated and maintained in Dulbecco’s minimal essential
medium (DMEM, Life Technologies, Carlsbad, CA) supple-
mented with glutamine, penicillin/streptomycin (pen-strep)
and 10 % fetal bovine serum. The immortalized human nor-
mal oral keratinocyte (iNOK) cell line; OKF6-TERT2, was
kindly provided by Dr. Cara Gonzales of UTHSCSA. This
cell line was maintained in keratinocyte serum-free media
(Life Technologies, Carlsbad, CA) supplemented with 25
ug/ml bovine pituitary extract (BPE), 0.2 ng/ml epidermal
growth factor (EGF) and 0.4 uM calcium chloride.
Animals
All protocols were approved by the Institutional Animal
Care and Use Committee of the University of Texas
Health Science Center at San Antonio. Male Sprague–
Dawley rats (Charles River Laboratories, Inc., Wilmington,
MA, USA) were used for all experiments. Animals were
housed for at least 7 days prior to the experiments.
Drugs
The TRPV1 antagonist, AMG517 was purchased from
Selleckchem (Houston, Texas, USA) and the TRPA1 an-
tagonist, HC030031 was purchased from Tocris (Ellsville,Missouri, USA). Both drugs were diluted in 10 % DMSO/
80 % mineral oil for peripheral injections and for systemic
injections, AMG517 was diluted in 10 % DMSO/4 %
Tween/PBS and HC030031 was diluted in 100 % DMSO.
Preparation of lipid extracts
Cells (3 × 105) were seeded per well of a 6-well plate.
Twenty-four hours later, media was changed to 2 ml of
basal minimal essential medium (MEM) without pH indi-
cator, without FBS and supplemented with glutamine and
pen-strep for OSCC cells and basal keratinocyte-serum
free media with pen-strep but without BPE, EGF or cal-
cium chloride. Following 24 hours, conditioned media was
harvested and cells were trypsinized and counted using
the TC20 automated cell counter (Bio-Rad). Conditioned
media was subjected to lipid extraction using the Folch’s
Method [29]. Briefly, 10 ml of chloroform: methanol (2:1)
was added to 2 ml of conditioned media and vortexed for
10 sec and incubated on ice for 30 min. The solution was
then vortexed again for 10 sec, washed with saline and
centrifuged at 8000 RPM for 10 min. The lower chloro-
form layer was collected and dried under nitrogen gas and
stored at −80 °C until further use. Light exposure was
minimized during lipid extraction. Immediately prior to
experiments, the dried extracts were re-suspended in
phosphate buffered saline.
Behavioral testing
All observers were blinded to treatment allocation. Three
behavioral assays were used in the study to measure spon-
taneous nocifensive as well as evoked nociception in
response to noxious stimuli. Spontaneous nocifensive be-
havior was carried out as described [30], whereas thermal
allodynia was measured using the radiant heat test [31]
and mechanical allodynia was measured using the dy-
namic aesthesiometer as described previously [32]. The
effect of OSCC-released lipids on nociception was studied
by injecting 50 ul of re-suspended lipid extract into the
plantar surface of the rat hindpaw. Nocifensive behavior
(defined as spontaneous flinching, flexion movements or
licking of the treated hindpaw) was recorded every 2 min
up to a total of 10 min. Thermal and mechanical thresh-
olds were measured from 10 to 150 min after injection.
To determine the role of TRPV1 and TRPA1 in mediat-
ing extract-induced nociceptive behaviors, animals were
pretreated with vehicle, AMG517 or HC030031 45 min
prior to extract injection. A systemic dose of 100 mg/kg of
either drug, subcutaneously underneath the neck, was given
for spontaneous nocifensive assays, whereas 100 ug of
either drug was injected intraplantarly in the hindpaw for
thermal and mechanical threshold measurements. The
doses for each drug were selected based on previously pub-
lished literature [33–36]. Nocifensive behavior was mea-
sured for 10 min whereas thermal and mechanical
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which was 10 min post injection of the lipid extract. Paw
withdrawal thresholds for ipsilateral as well as contralateral
hindpaws were measured.
Statistics
Data are presented as mean ± SEM. Statistical analyses
were performed using one-way or two-way ANOVA
with Sidak’s post-hoc test. A statistically significant dif-
ference was defined as P < 0.05. Error bars are standard
error of the mean (S.E.M).
Results
OSCC-released lipids induce nocifensive behavior in rats
in a TRPV1-dependent manner
Because oral cancer patients report spontaneous pain [5, 6],
we evaluated the role of OSCC-released lipids in triggering
spontaneous nocifensive behavior in rats. Intraplantar injec-
tion of lipid extracts from OSCC cell lines HSC2, HSC3
and HSC4 evoked spontaneous nocifensive behaviors in aFig. 1 Effect of OSCC-released lipids on nocifensive behavior of rats. Lipid ext
media of (a) immortalized normal oral keratinocyte (iNOK) cells and (b). HSC2,
the plantar surface of rat hindpaw and nocifensive behavior was measured up
50ul of PBS. Media group was injected with lipids extracted from media witho
error bars indicate SEM. Data were analyzed using two-way ANOVA with Sida
of harvest of conditioned media are indicated. c AMG517 (3 mg/kg) or HC030
1 hour later, lipid extract from HSC2 cells was injected in the rat hindpaw
represented as mean for each group and error bars indicate SEM. Data we
p <0.05. Asterisks indicate *p < 0.05; **p < 0.01; ***p < 0.001 and ****p < 0.0001
media are indicatedcell line-dependent manner (Fig. 1b). HSC2 produced the
greatest response, followed by HSC3, whereas HSC4 failed
to evoke a nocifensive response. The negative controls con-
sisted of phosphate buffered saline (PBS; used to solubilize
the lipid extracts) and lipid extracts from cell culture media
without exposure to cells; neither of these controls evoked
nocifensive behavior. To determine whether the effect of
these lipids was specific to cancer cells and not simply a
product of oral keratinocytes, we evaluated whether iNOK
cells release lipids capable of producing nocifensive behav-
ior. As seen in Fig. 1a, lipids extracts made from iNOK cells
did not evoke a nocifensive response more than the extracts
from the iNOK growth media alone. The iNOK growth
media itself showed a nocifensive response that could be
attributed to the basal media constituents required to
maintain the cells. Collectively, these data indicate that the
nocifensive effects of lipids are specific to OSCC cells.
To determine whether OSCC-released lipids induce
nocifensive behavior via activation of TRPV1 and/or
TRPA1, rats were pretreated with a systemic dose ofracts using the Folch’s extraction method were made from conditioned
HSC3 and HSC4 cells. 50ul of re-suspended extracts were injected into
to 10 min post injection. N = 6/group. Vehicle group was injected with
ut exposure to cells. Data are represented as mean for each group and
k’s post-hoc test with p <0.05. Average cell numbers per well at the time
031 (30 mg/kg) was injected subcutaneously underneath the neck and
and nocifensive behavior measured for 10 min. N =6/group. Data are
re analyzed using two-way ANOVA with Sidak’s post-hoc test with
. Average cell numbers per well at the time of harvest of conditioned
Fig. 2 Effect of OSCC-released lipids on thermal thresholds of rats. Lipid extracts using the Folch’s extraction method were made from conditioned
media of (a). iNOK, (b). HSC2, (c). HSC3 and (d). HSC4 cells. 50ul of re-suspended extracts were injected into the plantar surface of rat hindpaw and
thermal thresholds using the radiant heat test were measured up to 150 min post injection. N = 6/group. Vehicle group was injected with 50ul of PBS.
Data are represented as mean for each group and error bars indicate SEM. Data were analyzed using two-way ANOVA with Sidak’s post-hoc test with
p <0.05. Asterisks indicate *p < 0.05; **p < 0.01; ***p < 0.001 and ****p < 0.0001. Average cell numbers per well at the time of harvest of conditioned
media are indicated
Fig. 3 Effect of OSCC-released lipids on mechanical thresholds of rats. Lipid extracts using the Folch’s extraction method were made from
conditioned media of (a). iNOK, (b). HSC2, (c). HSC3 and (d). HSC4 cells. 50uls of re-suspended extracts were injected into the plantar surface of
rat hindpaw and mechanical thresholds using the dynamic aesthesiometer were measured up to 170 min post injection. N =6/group. Vehicle
group was injected with 50ul of PBS. Data are represented as mean for each group and error bars indicate SEM. Data were analyzed using two-way
ANOVA with Sidak’s post-hoc test with p <0.05. Asterisks indicate *p < 0.05; **p < 0.01; ***p < 0.001 and ****p < 0.0001. Average cell numbers per well at
the time of harvest of conditioned media are indicated
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ist (HC030031, 30 mg/kg) prior to injection of HSC2
lipid extract. As seen in Fig. 1c, AMG517 pretreatment
virtually abolished lipid-induced nocifensive behavior,
whereas HC030031 pretreatment had no effect.
OSCC-released lipids induce thermal and mechanical
allodynia in rats
We next evaluated the effect of OSCC-derived lipids on
thermal and mechanical thresholds. Figure 2b, c and d
demonstrated that injection of lipid extracts from HSC2
and HSC4 evoked significant thermal allodynia that
lasted up to 50–90 min depending on the cell line. Lipid
extracts from HSC3 did not produce a significant reduc-
tion in thermal escape thresholds. However, lipidFig. 4 Effect of TRP antagonists on Lipid-induced Thermal Allodynia. TRPV1
was injected in the ipsilateral rat hindpaw ipl 45 min prior to lipid extract injec
the ipsilateral and contralateral paws. a 50ul of re-suspended lipid extract mad
made from HSC4 cells was injected. c AMG517(100ug) or HC030031(100ug) w
lipid extract was injected in the ipsilateral paw. Thermal thresholds were meas
N = 6–8 /group. Vehicle group was injected with 50ul of 10%DMSO/90 % Min
group and error bars indicate SEM. Data were analyzed using two-way ANOV
**p < 0.01; ***p < 0.001 and ****p < 0.0001. Average cell numbers per well at t
the side where vehicle or drug was injectedextracts from all three-cell lines evoked significant
mechanical allodynia that lasted up to 50–150 min in a
cell line-dependent fashion (Fig. 3b, c and d). In con-
trast, lipids extracted from the iNOK cell line did not
evoke significant thermal or mechanical allodynia com-
pared to extracts made from growth media alone
(Figs. 2a and 3a).
OSCC-released lipids mediate thermal but not mechanical
allodynia via TRPV1 and TRPA1 channels
To evaluate whether OSCC-released lipids regulate periph-
eral activities of TRP channels, rats were pre-treated with
intraplantar injection of a vehicle, a TRPV1 antagonist
(AMG517) or a TRPA1 antagonist (HC030031) followed by
extract injection. Administration of the TRPV1 antagonistantagonist, AMG517 (100 ug) or TRPA1 antagonist HC030031 (100 ug)
tion. Thermal threshold were measured 10 min post extract injection of
e from HSC2 cells was injected. b 50 ul of re-suspended lipid extract
as injected in the contralateral rat hindpaw ipl and 45 min later, HSC2
ured 10 min post extract injection of ipsilateral and contralateral paws.
eral Oil. BL = Baseline thresholds. Data are represented as mean for each
A with Sidak’s post-hoc test with p <0.05. Asterisks indicate *p < 0.05;
he time of harvest of conditioned media are indicated. Arrows indicate
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cells and 92 % for HSC4 cells. Similarly pretreatment with
the TRPA1 antagonist reduced thermal allodynia by 83 %
for HSC2 cells and 76 % for HSC4 cells (Fig. 4). The antag-
onists did not have an effect on the contralateral paws. To
confirm that the effect of antagonist is peripheral and not
systemic, we injected AMG517 or HC030031 in contralat-
eral paw and 45 min later tested the effect of extract-
induced thermal allodynia in the ipsilateral paw. Figure 4c
shows that unlike injection of the TRP antagonist in the
ipsilateral paw, injection of antagonists in the contralateral
hindpaw had no effect on lipid-induced thermal allodynia.
These data indicate that the drug acts locally at the site of
injection. The effect of lipids released from HSC3 were not
further tested, as the lipid extracts did not produce substan-
tial thermal allodynia. Interestingly, neither the TRPV1 nor
the TRPA1 antagonists reversed lipid-induced mechanical
allodynia for any of the three cell lines (Fig. 5). TakenFig. 5 Effect of TRP antagonists on Lipid-induced Mechanical Allodynia. TR
(100 ug) was injected in the rat hindpaw ipl 45 min prior to lipid extract in
of the ipsilateral and contralateral paws. a 50ul of re-suspended lipid extrac
extract made from HSC3 cells was injected. c 50ul of re-suspended lipid ex
was injected with 50ul of 10%DMSO/90 % Mineral Oil. BL = Baseline thresh
indicate SEM. Data were analyzed using two-way ANOVA with Sidak’s post-ho
****p < 0.0001. Average cell numbers per well at the time of harvest of conditiotogether, these data suggests that lipids released by OSCC
cells induce thermal allodynia by regulating peripheral
TRPV1 and TRPA1 activities but these channels do not
mediate lipid-induced peripheral mechanical allodynia.
Discussion
Two distinct features of pain reports from oral cancer
patients are that: 1) the pain is specific to malignant le-
sions and is not observed in pre-cancerous or non-
cancerous lesions [37, 38]; and 2) significant pain occurs
even when the tumor is still quite small in size. These
aspects of oral cancer pain are consistent with the hy-
pothesis that oral squamous cell carcinoma cells directly
modulate activities of peripheral nociceptors. The TRP
channels are one class of receptors expressed on the
membranes of trigeminal primary afferents terminating
in the oral cavity [8–10, 21]. Recent reports have shown
that TRPV1 may play a role in oral cancer pain. ForPV1 antagonist, AMG517 (100 ug) or TRPA1 antagonist HC030031
jection. Thermal threshold were measured 10 min post extract injection
t made from HSC2 cells was injected. b 50ul of re-suspended lipid
tract made from HSC4 cells was injected. N = 6–8 /group. Vehicle group
olds. Data are represented as mean for each group and error bars
c test with p <0.05. Asterisks indicate *p < 0.05; **p < 0.01; ***p < 0.001 and
ned media are indicated
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increases after tumor growth in the oral cavity of rats [7]
and ablation of TRPV1+ neurons reduced OSCC-induced
thermal hyperalgesia [11]. The current study therefore
explored the mechanism by which TRPV1 activities are
regulated in peripheral sensory neurons during oral cancer
pain. Polyunsaturated fatty acids (PUFAs) are a possible
class of factors since human saliva from oral cancer pa-
tients has been reported to have elevated levels of certain
TRP-active PUFAs (e.g., linoleic acid, arachidonic acid,
HODE, and HETE), compared to normal control patients
[20], and many of these PUFAs activate TRPV1 [12–19] or
TRPA1 [12, 22–24]. We therefore evaluated the role of
OSCC-secreted lipids in mediating TRP-dependent oral
cancer pain using a combined approach of in vitro OSCC
cell cultures to generate lipid extracts followed by in vivo
measurement of nociception in rats. This approach focuses
on direct effects of tumor cells on peripheral nociceptors
without involvement of carcinogenesis, activation of the im-
mune system or alterations in the extracellular matrix.
It has been reported that most HNC patients reporting
pain have cancerous lesion in the mouth region [39]. We
therefore, used three human OSCC cell lines for our
study, namely, HSC2, HSC3 and HSC4, that were de-
rived from tumors obtained from patients with the pri-
mary site of tumor being either the floor of the mouth
or the tongue [28].
Our data demonstrate that lipids extracted from condi-
tioned media of the OSCC cell lines evoked nocifensive
behavior as well as significant thermal and mechanical
allodynia (Figs. 1a, 2b, c, and d and 3a, b, and c). Interest-
ingly, the responses observed for each of the three behav-
ioral modalities, were different between the three cell
lines. This finding of OSCC heterogeneity may contribute
to the observed high variation in pain intensity reported
by HNC patients. Importantly, these nociceptive sub-
stances appear to be derived from cancerous cells since
there were no nociceptive responses observed with lipid
extracts from normal oral keratinocyte cells. Moreover,
the collection of conditioned media precluded any contri-
bution from other cell types (e.g., immune cells, endothe-
lium, etc.) that might co-exist in a tumor mass grown
in vivo. Thus, OSCC release bioactive substances that
modulate nociceptor activity. Prior studies have reported
that OSCC cells may release certain protein or peptides
such as endothelin-1 [40], nerve growth factor (NGF) [41]
or trypsin [42], to activate peripheral afferents. However,
these and other hydrophilic compounds are excluded by
the Folch’s extraction method [29] and thus the present
findings demonstrate, for the first time, that lipids released
from OSCC cells may contribute to oral cancer pain.
The data also demonstrate a key role for TRPV1 in
mediating nociception induced by OSCC-derived lipid ex-
tracts. Pre-treatment with a TRPV1 antagonist completelyabolished lipid-mediated nocifensive responses and signifi-
cantly inhibited thermal allodynia. Further, the data indi-
cate that the site of action of the TRPV1 antagonist was
peripheral since injection of the drug in the contralateral
paw did not affect lipid-induced thermal allodynia. How-
ever, TRPV1 is not the only receptor system contributing
to lipid-induced nociception. This conclusion is based on
two findings. First, a TRPA1 antagonist had significant at-
tenuation of thermal allodynia. Second, neither the TRPV1
nor the TRPA1 antagonist altered mechanical allodynia
due to OSCC-derived lipids. Thus, OSCC-released lipids
evoke nociception via multiple mechanisms of action.
Identifying the specific lipids from OSCC cells can provide
further insights into mechanisms by which these lipids
induce oral cancer pain as well as, ways to target their
release for development of novel analgesics to treat oral
cancer pain.
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